Sublocade 300mg shortage – November 2021

A manufacturing issue has created a shortage of Sublocade 300mg in Australia. The 100mg strength is not affected. The shortage may have an impact on treating some patients.

Support and advice on managing patients during this shortage is available from the manufacturer, Indivior, as well as via your local PABN, including specialist clinical support, where available.

Find your local PABN contact here.

Contact Indivior via telephone 02 9025 0200 or email medinfoau@indivior.com.

COVID-19

The COVID-19 pandemic is presenting unique challenges for pharmacotherapy providers to provide continuum of care whilst also ensuring the safety of their patients and staff.

The Pharmacotherapy Area-Based Networks have been working closely with the Victorian Department of Health and Human Services, key stakeholders and providers to develop a series of guides for providing pharmacotherapy services during the COVID-19 pandemic. Find an overview with links to the guides on our new, dedicated COVID-19 page.

Get the guidelines now.